BioCryst Pharmaceuticals Inc. [BCRX] is 93.02% higher this YTD. Is it still time to buy?



BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] slipped around -0.89 points on Tuesday, while shares priced at $14.38 at the close of the session, down -5.83%. The company report on August 11, 2021 that BioCryst Withdraws Public Offering.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has withdrawn its proposed public offering. With our strong balance sheet, and increasing revenues from ORLADEYO® (berotralstat), we believe that current market conditions are not conducive to an offering on terms that would be in the best interests of our current stockholders. We are well capitalized, with cash, cash equivalents, restricted cash and investments of $222.8 million as of June 30, 2021. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


About BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals Inc. stock is now 93.02% up from its year-to-date (YTD) trading value. BCRX Stock saw the intraday high of $15.36 and lowest of $14.31 per share. The company’s 52-week high price is 18.48, which means current price is +97.80% above from all time high which was touched on 08/06/21.

Compared to the average trading volume of 3.38M shares, BCRX reached a trading volume of 4538672 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about BioCryst Pharmaceuticals Inc. [BCRX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $17.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on August 06, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on August 03, 2021, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $16, while Cowen analysts kept a Outperform rating on BCRX stock.

The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.98, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 33.50.

How has BCRX stock performed recently?

BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.43. With this latest performance, BCRX shares dropped by -6.62% in over the last four-week period, additionally plugging by 34.90% over the last 6 months – not to mention a rise of 217.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 38.19, with the RSI for the last a single of trading hit 33.75, and the three-weeks RSI is set at 41.71 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 16.34, while it was recorded at 15.60 for the last single week of trading, and 11.37 for the last 200 days.

BioCryst Pharmaceuticals Inc. [BCRX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.

Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.

Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.30.

Earnings analysis for BioCryst Pharmaceuticals Inc. [BCRX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 58.10%.

Insider trade positions for BioCryst Pharmaceuticals Inc. [BCRX]

There are presently around $1,505 million, or 60.90% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 15,481,327, which is approximately -4.682% of the company’s market cap and around 0.40% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $182.78 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $133.8 million in BCRX stock with ownership of nearly -4.078% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 99 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 16,594,685 shares. Additionally, 97 investors decreased positions by around 16,754,392 shares, while 30 investors held positions by with 71,296,004 shares. The mentioned changes placed institutional holdings at 104,645,081 shares, according to the latest SEC report filing. BCRX stock had 41 new institutional investments in for a total of 6,514,450 shares, while 36 institutional investors sold positions of 4,624,020 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam